These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 6329533)

  • 1. [Studies on new attenuated strains of type I live poliovirus vaccine. I. Development of Zhong I9 strain].
    Chen TQ; Li CZ; Ni SF; Ji GF; Shi M; Ye ZZ; Guo R; Dong DX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1983 Oct; 5(5):280-4. PubMed ID: 6329533
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on new attenuated strains of type I live poliovirus vaccine. II. Investigation on a series of field trials with "Zhong I9" strain].
    Chen TQ; Li CZ; Ni SF; Shi M; Luo GX; Dong DX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1983 Dec; 5(6):373-7. PubMed ID: 6327097
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on new attenuated strains of type III live poliomyelitis vaccine. I. Development of a new type III attenuated poliovirus.
    Chin Med J (Engl); 1980 Sep; 93(9):583-90. PubMed ID: 6253236
    [No Abstract]   [Full Text] [Related]  

  • 4. Inactivated poliovirus vaccine in Finland.
    Oker-Blom N; Penttinen K; Weckström P
    Rev Infect Dis; 1984; 6 Suppl 2():S461-2. PubMed ID: 6330842
    [No Abstract]   [Full Text] [Related]  

  • 5. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
    Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antigenicity determination of inactivated poliovirus--the micro-neutralization inhibition test].
    Jiang SD; Pye D
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Aug; 7(4):309-12. PubMed ID: 3011295
    [No Abstract]   [Full Text] [Related]  

  • 8. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
    Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of reactogenicity and immunogenicity of an oral and an inactivated polio vaccine.
    Borcić B; Dobrovsak-Sourek V; Kaić B; Ljubicić M
    Acta Med Croatica; 1998; 52(3):155-8. PubMed ID: 9818437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen.
    Salk J; Stoeckel P; van Wezel AL; Lapinleimu K; van Steenis G
    Ann Clin Res; 1982 Dec; 14(5-6):204-12. PubMed ID: 7171229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Observations on immune persistence after vaccination with attenuated polio vaccine (author's transl)].
    Shi OS
    Zhonghua Yu Fang Yi Xue Za Zhi; 1981 May; 15(3):148-50. PubMed ID: 7307827
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines.
    Vesikari T; Joensuu J; Baer M; Käyhty H; Olander RM; Sormunen H; Miettinen A; Ward RL; Guillot T
    Acta Paediatr; 1999 May; 88(5):513-20. PubMed ID: 10426173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies of purification, inactivity and immunogenicity of antigenically chimeric poliovirus].
    Cai H; Dai C
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Oct; 15(5):349-53. PubMed ID: 8168218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
    Rezapkin G; Martin J; Chumakov K
    Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine neurovirulence studies with a chimeric poliovirus: in vivo generation of a mutant base-paired stable attenuated poliovirus.
    Lee C; Young C
    Microb Pathog; 1998 Oct; 25(4):215-25. PubMed ID: 9817825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic PVR Tg-1 mice for testing of poliovirus type 3 neurovirulence: comparison with monkey test.
    Dragunsky E; Gardner D; Taffs R; Levenbook I
    Biologicals; 1993 Sep; 21(3):233-7. PubMed ID: 8117436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.